These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22873505)

  • 1. Glatiramer acetate induced hepatotoxicity.
    Subramaniam K; Pavli P; Llewellyn H; Chitturi S
    Curr Drug Saf; 2012 Apr; 7(2):186-8. PubMed ID: 22873505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis.
    La Gioia S; Bacis G; Sonzogni A; Frigeni B; Conti MZ; Vedovello M; Rottoli M
    Mult Scler Relat Disord; 2014 Nov; 3(6):732-4. PubMed ID: 25891553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
    Makhani N; Ngan BY; Kamath BM; Yeh EA
    Neurology; 2013 Aug; 81(9):850-2. PubMed ID: 23884038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
    Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate for the treatment of multiple sclerosis.
    Wolinsky JS
    Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
    Antezana A; Herbert J; Park J; Kister I
    Neurology; 2014 May; 82(20):1846-7. PubMed ID: 24843037
    [No Abstract]   [Full Text] [Related]  

  • 7. [Autoimmune hepatitis in a patient with multiple sclerosis under treatment with glatiramer acetate].
    Arruti M; Castillo-Triviño T; de la Riva P; Martí-Massó JF; López de Munain A; Olascoaga J
    Rev Neurol; 2012 Aug; 55(3):190-2. PubMed ID: 22825980
    [No Abstract]   [Full Text] [Related]  

  • 8. Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.
    Neumann H; Csepregi A; Sailer M; Malfertheiner P
    J Neurol; 2007 Jun; 254(6):816-7. PubMed ID: 17351724
    [No Abstract]   [Full Text] [Related]  

  • 9. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis--not only beta interferon.
    von Kalckreuth V; Lohse AW; Schramm C
    Am J Gastroenterol; 2008 Aug; 103(8):2147-8; author reply 2148. PubMed ID: 18796115
    [No Abstract]   [Full Text] [Related]  

  • 11. [Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
    Demina TL; Davydovskaia MV; Lashch NIu; Popova NF; Khachanova NV; Zhuchenko TD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):91-7. PubMed ID: 12938642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
    Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
    Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
    Galetta SL; Markowitz C; Lee AG
    Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glatiramer acetate for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 1997 Jul; 39(1004):61-2. PubMed ID: 9217693
    [No Abstract]   [Full Text] [Related]  

  • 17. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
    Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M
    Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced liver injury after high-dose methylprednisolone in a patient with multiple sclerosis.
    Oliveira AT; Lopes S; Cipriano MA; Sofia C
    BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26199298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK; Butler JS; Mattingly M; Ryan M
    J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of glatiramer acetate in clinical practice: an observational study.
    Fernández-Fernández Ó; Garcia-Trujillo L; Guerrero-Fernández M; León A; López-Madrona JC; Alonso A; Bustamante R; Fernández-Sánchez VE
    Rev Neurol; 2012 Jan; 54(1):1-9. PubMed ID: 22187206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.